

# Philippe Séguéla, Ph. D.

Professor  
Department of Neurology & Neurosurgery  
McGill University

## *The analgesic role of prefrontal dopamine in chronic pain*

**Vendredi 21 octobre 2022**

12 h à 13 h

### En présentiel

Pavillon Paul-G.-Desmarais | 2960, chemin de la Tour, **local 1120**

### En ligne

<https://umontreal.zoom.us/j/88066173443?pwd=ajlvdzA0a09FSGlFc3NuRUdFNVhNdz09>

### **Biographie**

Dr. Philippe Séguéla, PhD is Full Professor in the department of Neurology & Neurosurgery of McGill University. Trained in neuroscience in France, Canada and the US, his world-renowned research funded by CIHR, NSERC and private foundations is primarily focused on ion channels contributing to neuronal hyperexcitability in pain circuits. His lab located in the famous Montreal Neurological Institute uses a multidisciplinary approach including state-of-the-art molecular pharmacology, transgenic mouse models, optogenetics, chemogenetics, transcriptomics, calcium imaging, electrophysiology and quantitative behavioural sensory assays to investigate key neuronal mechanisms in peripheral and central pain pathways. He is the scientific founder of the McGill spinoffs and biotech companies Antalium (1999), PainCeptor Pharma (2004), Neurasic Therapeutics (2020). The long-term goals of Dr. Séguéla's team and collaborators are to elucidate the cellular basis of sensory hypersensitivity observed in chronic pain patients and to discover innovative clinical strategies for non-opioid analgesia.

### **Entrée libre**

Personnes-ressources pour rencontrer le conférencier : [nicole.leclerc@umontreal.ca](mailto:nicole.leclerc@umontreal.ca) et [r.becket.ebits@umontreal.ca](mailto:r.becket.ebits@umontreal.ca)